AR023633A1 - USE OF A LANREOTIDE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT - Google Patents
USE OF A LANREOTIDE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND A PHARMACEUTICAL COMPOSITION THAT INCLUDES ITInfo
- Publication number
- AR023633A1 AR023633A1 ARP990103765A ARP990103765A AR023633A1 AR 023633 A1 AR023633 A1 AR 023633A1 AR P990103765 A ARP990103765 A AR P990103765A AR P990103765 A ARP990103765 A AR P990103765A AR 023633 A1 AR023633 A1 AR 023633A1
- Authority
- AR
- Argentina
- Prior art keywords
- lanreotide
- syndrome
- manufacture
- disease
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Uso de un lanreotido para la manufactura de un medicamento util para el tratamiento de una enfermedad o afeccion caracterizado porque comprende administrara un paciente que lo necesita, una cantidad eficaz del compuesto H-beta-D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH (conocido también como lanreotido)donde las dosCisteínas están unidas por un enlace disulfuro o una sal farmacéuticamente aceptable del mismo, donde la enfermedad o afeccion está seleccionada del grupo queconsiste en esclerosis sistémica pseudocistos pancreáticos ascitis pancreática, VIPoma, nesidoblastosis, hiperinsulinismo, gastrinoma, síndrome de Zollinger-Ellison, diarrea hipersecretora escleroderma, síndrome de intestino irritable, sangrado gastrointestinal superior, hipertension venosa portal postprandial,complicaciones de hipertension potal, obstruccion del intestino delgado, reflujo gastroesofagal, reflujo duodenogástrico, Síndrome de Cushing, gonadotropinoma,hiperparatiroidismo, neuropatía diabética, degeneracion macular, hipercalcemia de malignidad, enfermedad de Paget, meningioma caquexia de cáncer, hipotensiony ataques de pánico, uso de un lanréotido para la manufactura de un medicamento y una composicion farmacéutica que lo comprende.Use of a lanreotide for the manufacture of a medicament useful for the treatment of a disease or condition characterized in that it comprises administering a patient in need thereof, an effective amount of the compound H-beta-D-Nal-Cys-Tyr-D-Trp- Lys-Val-Cys-Thr-NH (also known as lanreotide) where the two cysteines are linked by a disulfide bond or a pharmaceutically acceptable salt thereof, where the disease or condition is selected from the group consisting of systemic sclerosis, pancreatic ascites, pancreatic ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison syndrome, scleroderma hypersecretory diarrhea, irritable bowel syndrome, upper gastrointestinal bleeding, postprandial portal venous hypertension, complications of potal hypertension, obstruction of the small intestine, gastroesophageal reflux, duodenal reflux syndrome, duodenal reflux syndrome, duodenal reflux syndrome Cushing, gonadotropinoma, hyperparathyroidism, diabetic neuropathy, d macular degeneration, hypercalcemia of malignancy, Paget's disease, cancer cachexia meningioma, hypotension and panic attacks, use of a lanreotide for the manufacture of a drug and a pharmaceutical composition that comprises it.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9469398P | 1998-07-30 | 1998-07-30 | |
| US12652598A | 1998-07-30 | 1998-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR023633A1 true AR023633A1 (en) | 2002-09-04 |
Family
ID=26789150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990103765A AR023633A1 (en) | 1998-07-30 | 1999-07-29 | USE OF A LANREOTIDE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1100532A2 (en) |
| JP (1) | JP2002521456A (en) |
| KR (1) | KR20010071071A (en) |
| CN (1) | CN1334742A (en) |
| AR (1) | AR023633A1 (en) |
| AU (2) | AU770193B2 (en) |
| BR (1) | BR9912609A (en) |
| CA (1) | CA2335654A1 (en) |
| CZ (1) | CZ2001157A3 (en) |
| HU (1) | HUP0102839A3 (en) |
| IL (2) | IL140837A0 (en) |
| MX (1) | MXPA01000969A (en) |
| NO (1) | NO324123B1 (en) |
| NZ (1) | NZ509348A (en) |
| PL (1) | PL346361A1 (en) |
| WO (1) | WO2000006185A2 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1040837A3 (en) * | 1999-02-26 | 2002-01-02 | Erasmus Universiteit Rotterdam | Medicaments for the treatment of a choroidal neovascularization (CNV) related disorder |
| AU2001283957A1 (en) * | 2000-07-27 | 2002-02-13 | Novartis Ag | Treatment of ocular disorders with somatostatin analogues |
| US6316414B1 (en) | 2000-07-31 | 2001-11-13 | Dabur Research Foundation | Somatostatin analogs for the treatment of cancer |
| ES2345280T3 (en) | 2001-03-06 | 2010-09-20 | The Administrators Of The Tulane Educational Fund | PROCEDURE FOR MODULATION OF THE PROLIFERATION OF MEDULAR THYROID CARCINOMA CELLS. |
| GB0109461D0 (en) * | 2001-04-18 | 2001-06-06 | Univ London | New Gene |
| WO2003061592A2 (en) | 2002-01-22 | 2003-07-31 | New York University | Methods for therapeutic treatment of benign prostatic hypertrophy (bph) |
| CN107446053A (en) | 2008-06-12 | 2017-12-08 | 益普生生物创新有限公司 | The suppression of cancer |
| KR101642363B1 (en) | 2008-06-12 | 2016-07-25 | 입센 바이오이노베이션 리미티드 | Suppression of neuroendocrine diseases |
| GB0820970D0 (en) | 2008-11-17 | 2008-12-24 | Syntaxin Ltd | Suppression of cancer |
| CN101935252B (en) * | 2010-07-29 | 2013-01-30 | 广东省农业科学院科技情报研究所 | Landscape plant growth retardant and preparation method thereof |
| BR112014025058B1 (en) * | 2012-04-12 | 2022-07-12 | Novartis Ag | COMBINATION OF SOMATOSTATIN ANALOGS WITH 11BETA-HYDROXYLASE INHIBITORS, AND THEIR USES |
| CN105168115A (en) * | 2015-09-02 | 2015-12-23 | 中国药科大学 | Oral medication path of somatostatin analogue polypeptide drug |
| WO2017212390A1 (en) * | 2016-06-06 | 2017-12-14 | Emcure Pharmaceuticals Ltd, | Process for lanreotide acetate preparation |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4853371A (en) * | 1986-06-17 | 1989-08-01 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
| US5538739A (en) * | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| ATE140237T1 (en) * | 1989-12-08 | 1996-07-15 | Univ Tulane | OCTAPEPTIDE ANALOGUES OF SOMATOSTATIN WITH THREONINE IN POSITION 6 |
| WO1998008528A1 (en) * | 1996-08-30 | 1998-03-05 | Biomeasure Incorporated | Method of inhibiting fibrosis with a somatostatin agonist |
| WO1998010786A2 (en) * | 1996-09-12 | 1998-03-19 | Yarom Cohen | Pharmaceutical composition for the treatment of syndrome x of reaven |
| DE69822810T2 (en) * | 1997-05-13 | 2005-02-03 | Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. | SOMATOSTATIN AND SOMATOSTATIN AGONIST FOR THE TREATMENT OF INSULIN SENSITIVITY AND SYNDROME X |
-
1999
- 1999-07-29 NZ NZ509348A patent/NZ509348A/en unknown
- 1999-07-29 AU AU52447/99A patent/AU770193B2/en not_active Ceased
- 1999-07-29 CN CN99808953A patent/CN1334742A/en active Pending
- 1999-07-29 WO PCT/US1999/017294 patent/WO2000006185A2/en not_active Application Discontinuation
- 1999-07-29 CA CA002335654A patent/CA2335654A1/en not_active Abandoned
- 1999-07-29 KR KR1020017001277A patent/KR20010071071A/en not_active Application Discontinuation
- 1999-07-29 CZ CZ2001157A patent/CZ2001157A3/en unknown
- 1999-07-29 MX MXPA01000969A patent/MXPA01000969A/en unknown
- 1999-07-29 HU HU0102839A patent/HUP0102839A3/en unknown
- 1999-07-29 BR BR9912609-5A patent/BR9912609A/en not_active IP Right Cessation
- 1999-07-29 PL PL99346361A patent/PL346361A1/en unknown
- 1999-07-29 AR ARP990103765A patent/AR023633A1/en unknown
- 1999-07-29 JP JP2000562039A patent/JP2002521456A/en active Pending
- 1999-07-29 IL IL14083799A patent/IL140837A0/en unknown
- 1999-07-29 EP EP99937658A patent/EP1100532A2/en not_active Withdrawn
-
2001
- 2001-01-29 NO NO20010481A patent/NO324123B1/en not_active IP Right Cessation
-
2004
- 2004-04-29 AU AU2004201783A patent/AU2004201783A1/en not_active Abandoned
-
2007
- 2007-02-15 IL IL181349A patent/IL181349A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CZ2001157A3 (en) | 2002-02-13 |
| PL346361A1 (en) | 2002-02-11 |
| IL181349A0 (en) | 2007-07-04 |
| KR20010071071A (en) | 2001-07-28 |
| HUP0102839A2 (en) | 2002-01-28 |
| MXPA01000969A (en) | 2003-04-07 |
| AU770193B2 (en) | 2004-02-12 |
| NO20010481L (en) | 2001-03-21 |
| WO2000006185A2 (en) | 2000-02-10 |
| HUP0102839A3 (en) | 2002-02-28 |
| CN1334742A (en) | 2002-02-06 |
| BR9912609A (en) | 2001-05-02 |
| JP2002521456A (en) | 2002-07-16 |
| AU2004201783A1 (en) | 2004-05-27 |
| NZ509348A (en) | 2004-02-27 |
| IL140837A0 (en) | 2002-02-10 |
| WO2000006185A3 (en) | 2000-08-03 |
| NO324123B1 (en) | 2007-08-27 |
| AU5244799A (en) | 2000-02-21 |
| NO20010481D0 (en) | 2001-01-29 |
| EP1100532A2 (en) | 2001-05-23 |
| CA2335654A1 (en) | 2000-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR023633A1 (en) | USE OF A LANREOTIDE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT | |
| RU2219167C2 (en) | N-substituted aminotetralines as ligands for receptor of y5 of neuropeptide y useful in treatment of obesity and other disorders | |
| DE60032926T2 (en) | IMPROVEMENT OF PEPTIDE TRANSPORT BY CONJUGATION WITH GALLEN ACIDS | |
| EP1288223B1 (en) | Therapeutic peptide derivatives | |
| US10413594B2 (en) | Conjugates of somatostatin analogues | |
| CN112043835B (en) | Bioreversible introducing group for nitrogen and hydroxyl-containing drugs | |
| JP2021100937A5 (en) | ||
| ATE541582T1 (en) | STABILIZED PHARMACEUTICAL GLP-1 PEPTIDE COMPOSITIONS | |
| JP2007528354A (en) | Reversible PEGylated drug | |
| JP2006520818A (en) | Polyethylene glycol-linked GLP-1 compound | |
| US9303067B2 (en) | Sustained release formulation comprising a somatostatin analogue | |
| KR20050033563A (en) | Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses | |
| JP2008526846A (en) | Analgesic conjugate | |
| Gregor et al. | Effect of monoclonal antibodies to enteroglucagon on ileal adaptation after proximal small bowel resection. | |
| JP2022504596A (en) | Human amylin analog peptide and how to use | |
| AU2007218297A1 (en) | Combination of Somatostatin-analogs with different selectivity for human Somatostatin receptor subtypes | |
| AR029637A1 (en) | GUANIDINE COMPOUNDS, ANTAGONISTS OF IL-8 RECEPTORS, A PHARMACEUTICAL COMPOSITION CONTAINING THEM AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT | |
| RU2004121687A (en) | COMPOSITIONS CONTAINING EPOTHYLONS AND THEIR APPLICATION FOR TREATMENT OF A CARCINOID SYNDROME | |
| US6150333A (en) | Methods of using a somatostatin analogue | |
| JPH0615558B2 (en) | Novel polypeptide, production method and medicine | |
| KR950701344A (en) | Endothelin Antagonists II | |
| US5622709A (en) | Cimetidine-phenol pharmaceutical composition | |
| RU2001105926A (en) | WAYS OF APPLICATION ANALOGUE OF SOMATOSTATIN | |
| EP1291022A1 (en) | Methods of using lanreotide, a somatostatin analogue | |
| Choi | Intestinotrophic effect of a novel long-acting GLP-2 analog, HM15912, in animal model of short bowel syndrome and potential as monthly administration |